Find the latest science, technology and partners in antibody engineering, immunobiology and next generation binders.

Strategies to Innovate the Production of Next Generation Bioconjugates

Share this article

From ADC development to tumor-targeting, there are still many lessons to be learned in the world of conjugation.

This whitepaper reviews the latest common challenges and novel strategies for accelerating bioconjugates, across preclinical, research & development and CMC considerations.

It includes:

  • Antibody, site, linker & payload combinations to optimize ADCs
  • Improved targeting for solid tumors
  • Novel payloads and delivery vehicles including antibody fragment–drug, centyrin, peptide drug and oligonucleotide conjugates

To read the whitepaper, just click on the image below. 

Whitepaper: Strategies to Innovate Bioconjugates

Have any questions about the report or interested in sponsoring a future whitepaper? Email andrew.burrows@informa.com.

Share this article

Upcoming event

Antibody Engineering & Therapeutics US

14 - 16 Dec 2020, Delivered in Eastern Standard Time (EST)
THE #1 ANTIBODY ENGINEERING CONFERENCE FOR ACCELERATING NEXT GENERATION ANTIBODIES TO COMMERCIAL SUCCESS
Go to site